( Scientists to Present Data on Innovativ...)Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer,Health

ABBOTT PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- For decades, scientists have looked for new therapies that target cancer. Researchers now know that cancer cells have several unique characteristics -- they require new blood vessels to deliver oxygen and nutrients (angiogenesis), they grow uncontrollably (proliferation), they travel throughout the body (metastasis), and they escape programmed cell death, a natural process by which the body rids itself of damaged or unwanted cells (apoptosis). Robust preclinical data shows that several compounds in Abbott's oncology pipeline interfere with these vital processes. Data on two of these compounds will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-18 in Los Angeles.

During the meeting, scientists from independent academic institutions and Abbott will present data on Abbott's Bcl-2 family protein inhibitor (ABT-263). This compound, currently in early clinical development, corrects defects in cancer cells that allow them to escape programmed cell death. They will also present data on an investigational PARP inhibitor (ABT-888) that enhances the effectiveness of common cancer therapies that damage DNA in cancer cells.

    Presentation highlights include:


    ABT-263

    --  "ABT-263:  An orally bioavailable Bcl-2 family protein inhibitor"

        [Oral presentation, Sunday, April 15, 1 p.m., Hall A]

    --  "Pediatric preclinical testing program (PPTP) evaluation of the Bcl-2

         inhibitor ABT-263"

        [Oral presentation, Tuesday, April 17, 3:55 p.m., Room 404 A-B]


    ABT-888

    --  "The poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888 potentiates

         the antitumor activity of temozolomide in the B16F10 syngeneic

         melanoma model: Correlation with pharmacokinetic levels and a

  
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V
Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results
in Phase II Psoriasis Study
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and
Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to
Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the

American College of Cardiologys 56th Annual Scientific Session
10. NIEHS Researchers Identify Enzyme Critical in DNA Replication
11. Stanford Researchers Find Brain Pathway of Depression in Rats